Eudald Felip Falgàs
Eudald Felip graduated with a degree in Medicine from the Autonomous University of Barcelona (UAB). He completed his specialization in medical oncology in 2018, at the Germans Trias i Pujol University Hospital, and currently he is a member of the Breast Cancer Unit of the Catalan Institute of Oncology (ICO-Badalona). He focuses his research on finding biomarkers in CDK4/6 inhibitors treatment in metastatic breast cancer. He has participated in different internationals congresses and has several publications in international journals. He collaborates with the IrsiCaixa VIH Pathogenesis group since March 2018.
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection.
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation.